3-ethynyltetrahydro-2H-pyran-3-ol | 1394119-79-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 氧烷类
• 英文名称: 3-ethynyltetrahydro-2H-pyran-3-ol
• 英文别名: 3-ethynyloxan-3-ol
• CAS: 1394119-79-9
• 化学式: C₇H₁₀O₂
• 分子量: 126.155
• InChiKey: AXEGWTIRZGZOCV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  9
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  29.5
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-((1-(4-amino-1,3,5-triazin-2-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)ethynyl)bicyclo[2.2.1]heptan-2-ol 、 3-ethynyltetrahydro-2H-pyran-3-ol 在 title product 、 3-((1-(4-amino-1,3,5-triazin-2-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)ethynyl)tetrahydro-2H-pyran-3-ol 、 silica gel 作用下， 生成 3-((1-(4-amino-1,3,5-triazin-2-yl)-2-methyl-1H-benzo[d]imidazol-6-yl)ethynyl)tetrahydro-2H-pyran-3-ol
  参考文献：
  名称：

  6,5-heterocyclic propargylic alcohol compounds and uses therefor

  摘要：

  本发明涉及一种新型化合物I的公式：其中A，Y，R1，R2和下标b具有如下所述的含义，以及化合物I的立体异构体，几何异构体，互变异构体，溶剂化物，代谢物，同位素，药学上可接受的盐或其前药。公式I化合物及其制药组合物在治疗疾病和障碍方面有用，其中观察到NF-kB信号的不良或过度激活。

  公开号：

  US08901313B2

文献信息

• Ring Expansion and Rearrangements of Rhodium(II) Azavinyl Carbenes
  作者：Nicklas Selander、Brady T. Worrell、Valery V. Fokin

  DOI：10.1002/anie.201207820

  日期：2012.12.21

  regioselective, and convergent method for the ring expansion and rearrangement of 1‐sulfonyl‐1,2,3‐triazoles under rhodium(II)‐catalyzed conditions is described. These denitrogenative reactions form substituted enaminone and olefin‐based products (see scheme). The enaminone products can be further functionalized to give various heterocycles and ketone derivatives, thus rendering the sulfonyl triazole traceless

  扩展空间：描述了一种在铑 (II) 催化条件下进行 1-磺酰基-1,2,3-三唑环扩展和重排的有效、区域选择性和收敛方法。这些脱氮反应形成取代的烯胺酮和基于烯烃的产物（参见方案）。烯胺酮产物可以进一步官能化，得到各种杂环和酮衍生物，从而使磺酰三唑变得无痕。
• 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR
  申请人：Staben Steven

  公开号：US20120214762A1

  公开（公告）日：2012-08-23

  The invention relates to novel compounds of Formula I: wherein A, Y, R 1 , R 2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  这项发明涉及公式I的新化合物： 其中A、Y、R1、R2和下标b各自具有如本文所述的含义，以及公式I的化合物、立体异构体、几何异构体、互变异构体、溶剂合物、代谢物、同位素、药学上可接受的盐或其前药。公式I的化合物及其药物组成物在治疗观察到NF-kB信号通路的不良或过度激活的疾病和紊乱中是有用的。
• [EN] SERINE/THREONINE KINASE INHIBITORS<br/>[FR] INHIBITEURS DE SÉRINE/THRÉONINE KINASES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2014170421A1

  公开（公告）日：2014-10-23

  Compounds having the formula (I) wherein R1, R2, R3 and X are as defined herein are inhibitors of Group II PAK kinases. Also disclosed are compositions and methods for limiting cell motility and metatasis.

  具有化学式（I）的化合物，其中R1、R2、R3和X的定义如本文所述，是Ⅱ类PAK激酶的抑制剂。还公开了限制细胞运动和转移的组合物和方法。
• 6,5-heterocyclic propargylic alcohol compounds and uses therefor
  申请人：Staben Steven

  公开号：US08901313B2

  公开（公告）日：2014-12-02

  The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.

  本发明涉及一种新型化合物I的公式：其中A，Y，R1，R2和下标b具有如下所述的含义，以及化合物I的立体异构体，几何异构体，互变异构体，溶剂化物，代谢物，同位素，药学上可接受的盐或其前药。公式I化合物及其制药组合物在治疗疾病和障碍方面有用，其中观察到NF-kB信号的不良或过度激活。
• Back Pocket Flexibility Provides Group II p21-Activated Kinase (PAK) Selectivity for Type I 1/2 Kinase Inhibitors
  作者：Steven T. Staben、Jianwen A. Feng、Karen Lyle、Marcia Belvin、Jason Boggs、Jason D. Burch、Ching-ching Chua、Haifeng Cui、Antonio G. DiPasquale、Lori S. Friedman、Christopher Heise、Hartmut Koeppen、Adrian Kotey、Robert Mintzer、Angela Oh、David Allen Roberts、Lionel Rouge、Joachim Rudolph、Christine Tam、Weiru Wang、Yisong Xiao、Amy Young、Yamin Zhang、Klaus P. Hoeflich

  DOI：10.1021/jm401768t

  日期：2014.2.13

  Structure-based methods were used to design a potent and highly selective group II p21-activated kinase (PAK) inhibitor with a novel binding mode, compound 17. Hydrophobic interactions within a lipophilic pocket past the methionine gatekeeper of group II PAKs approached by these type I 1/2 binders were found to be important for improving potency. A structure-based hypothesis and strategy for achieving selectivity over group I PAKs, and the broad kinome, based on unique flexibility of this lipophilic pocket, is presented. A concentration-dependent decrease in tumor cell migration and invasion in two triple-negative breast cancer cell lines was observed with compound 17.